241 related articles for article (PubMed ID: 30460631)
1. Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.
Liu Z; Che P; Mercado JJ; Hackney JR; Friedman GK; Zhang C; You Z; Zhao X; Ding Q; Kim K; Li H; Liu X; Markert JM; Nabors B; Gillespie GY; Zhao R; Han X
J Neurooncol; 2019 Jan; 141(2):289-301. PubMed ID: 30460631
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
3. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733
[No Abstract] [Full Text] [Related]
4. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
5. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
[TBL] [Abstract][Full Text] [Related]
7. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
9. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
10. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
14. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
15. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
19. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
[TBL] [Abstract][Full Text] [Related]
20. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]